| Literature DB >> 27872090 |
Ling-Wen Ding1, Qiao-Yang Sun1, Kar-Tong Tan1, Wenwen Chien1, Anand Mayakonda1, Allen Eng Juh Yeoh1, Norihiko Kawamata2,3, Yasunobu Nagata4, Jin-Fen Xiao1, Xin-Yi Loh1, De-Chen Lin1,3, Manoj Garg1, Yan-Yi Jiang1, Liang Xu1, Su-Lin Lim1, Li-Zhen Liu1, Vikas Madan1, Masashi Sanada4, Lucia Torres Fernández1, S S Hema Preethi1, Michael Lill3, Hagop M Kantarjian5, Steven M Kornblau5, Satoru Miyano6,7, Der-Cherng Liang8, Seishi Ogawa4, Lee-Yung Shih9, Henry Yang1, H Phillip Koeffler1,3.
Abstract
Current standard of care for patients with pediatric acute lymphoblastic leukemia (ALL) is mainly effective, with high remission rates after treatment. However, the genetic perturbations that give rise to this disease remain largely undefined, limiting the ability to address resistant tumors or develop less toxic targeted therapies. Here, we report the use of next-generation sequencing to interrogate the genetic and pathogenic mechanisms of 240 pediatric ALL cases with their matched remission samples. Commonly mutated genes fell into several categories, including RAS/receptor tyrosine kinases, epigenetic regulators, transcription factors involved in lineage commitment, and the p53/cell-cycle pathway. Unique recurrent mutational hotspots were observed in epigenetic regulators CREBBP (R1446C/H), WHSC1 (E1099K), and the tyrosine kinase FLT3 (K663R, N676K). The mutant WHSC1 was established as a gain-of-function oncogene, while the epigenetic regulator ARID1A and transcription factor CTCF were functionally identified as potential tumor suppressors. Analysis of 28 diagnosis/relapse trio patients plus 10 relapse cases revealed four evolutionary paths and uncovered the ordering of acquisition of mutations in these patients. This study provides a detailed mutational portrait of pediatric ALL and gives insights into the molecular pathogenesis of this disease. Cancer Res; 77(2); 390-400. ©2016 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh:
Year: 2016 PMID: 27872090 PMCID: PMC5243866 DOI: 10.1158/0008-5472.CAN-16-1303
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701